The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | PROTACs: potential novel agents for the treatment of CLL
In this video, Deepa Sampath, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, introduces proteolysis targeting chimeras (PROTACs) and outlines how these agents have been investigated in chronic lymphocytic leukemia (CLL) cells, in which they target BCL2 and Bcl-xL (PROTACs PZ18753b and WH25244). Dr Sampath hopes to introduce these agents to the clinic by 2024, as they are effective in both venetoclax-sensitive and venetoclax-resistant CLL. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
